Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 600-606

  Rubin, Joseph ^a   Ajani, Jaffer ^a   Schirmer, William ^a   Venook, Alan P ^a   Bukowski, Ronald ^a   Pommier, Rodney ^a   Saltz, Leonard ^a   Dandona, Paresh ^a   Anthony, Lowell ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; OCTREOTIDE;

ADULT; AGED; ARTICLE; CARCINOID SYNDROME; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUSHING; FOLLOW UP; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STEADY STATE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0033053184     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.600     Document Type: Article

References (21)

1. Kvols LK: Metastatic carcinoid tumors and the malignant carcinoid syndrome. Ann NY Acad Sci 733:464-470, 1994
2. Roberts LJ II, Anthony LB, Oates JA: Disorders of vasodilator hormones: The carcinoid syndrome and mastocytosis, in Wilson JD, Foster DW (eds): Williams Textbook of Endocrinology (ed 9). Philadelphia, PA, WB Saunders, 1998, pp 1619-1634
3. Redfern J, O'Dorisio TM: Gastrointestinal hormones and carcinoid syndrome, in Felig P, Baxter JD, Frohman LA (eds): Endocrinology and Metabolism (ed 3). New York, NY, McGraw-Hill, 1995, pp 1675-1700
4. Newton JN, Swerdlow AJ, dos Santos Silva IM, et al: The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer 70:939-942, 1994
5. Godwin JD II: Carcinoid tumors: An analysis of 2837 cases. Cancer 36:560-569, 1975
6. Surveillance, Epidemiology, and End-Results (SEER): Cancer Statistics Review. Bethesda, MD, U.S. Department of Health and Human Services, Public Health Institute, National Institutes of Health, National Cancer Institute, 1993
7. Modlin IM, Sandor A: An analysis of 8305 cases of carcinoid tumors. Cancer 79:813-829, 1997
8. Kaplan LM: Endocrine tumors of the gastrointestinal tract and pancreas, in Isselbacher KJ, Braunwald E, Wilson JD, et al (eds): Harrison's Principles of Internal Medicine (ed 13). New York, NY, McGraw-Hill, 1994, pp 1535-1542
9. Janmohamed S, Bloom SR: Carcinoid tumours. Postgrad Med J 73:207-214, 1997
10. Gorden P, Comis RJ, Maton PN, et al: Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 110:35-50, 1989
11. Kvols LK, Moertel CG, O'Connell MJ, et al: Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue. N Engl J Med 315:663-666, 1986
12. Norton JA, Levin B, Jensen RT: Cancer of the endocrine system, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 1333-1435
13. Buchanan KD: Effects of Sandostatin on neuroendocrine tumours of the gastrointestinal system. Recent Results Cancer Res 129:45-55, 1993
14. Creutzfeldt W: Carcinoid tumors: Development of our knowledge. World J Surg 20:126-131, 1996
15. Lancranjan I, Bruns C, Grass P, et al: Sandostatin LAR®: A promising therapeutic tool in the management of acromegalic patients. Metabolism 45:67-71, 1996 (suppl 1)
16. Lancranjan I, Bruns C, Grass P, et al: Sandostatin LAR®: Pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients. Metabolism 44:18-26, 1995
17. Bax ND, Woods HF, Batchelor A, et al: Octreotide therapy in carcinoid disease. Anticancer Drugs 7:17-22, 1996 (suppl 1)
18. Creutzfeldt W, Stöckmann F: Carcinoids and carcinoid syndrome. Am J Med 82:4-16, 1987 (suppl 5B)
19. Harris AG, O'Dorisio TM, Woltering EA, et al: Consensus statement: octreotide dose titration in secretory diarrhea: Diarrhea Management Consensus Development Panel. Dig Dis Sci 40:1464-1473, 1995
20. Battershill PE, Clissold SP: Octreotide: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 38:658-702, 1989
21. Plockinger U, Dienemann D, Quabbe HJ: Gastrointestinal side effects of octreotide during long term treatment of acromegaly. J Clin Endocrinol Metab 71:1658-1662, 1990